Abstract: One can identify and quantify one or more glycosylation markers of a physiological condition such as a disease or a stage of disease by utilizing quantitative HPLC analysis of glycans which have been released from unpurified glycoproteins. The unpurified glycoproteins can be total glycoproteins or a selection of the total glycoproteins. The identified glycosylation marker can be a native glycan or a digestion product which has been segregated and amplified by exoglycosidase digestions. This strategy is compatible with a high throughput format and glycan data base searching. One can utilize the identified glycosylation marker, for example, for monitoring the physiological condition in a subject. One can also use the glycosylation marker to identify glycoproteins that carry the glycosylation marker which can also be used to monitor the physiological condition. The biomarker may also be a subset of glycoforms of a glycoprotein that are separated in trains of spots on 2D gel.

Abstract: One can identify and quantify one or more glycosylation markers of cancer by utilizing quantitative HPLC analysis of glycans which have been released from unpurified glycoproteins. The unpurified glycoproteins can be total glycoproteins or a selection of the total glycoproteins. The identified glycosylation marker can be a native glycan or a digestion product which has been segregated and amplified by exoglycosidase digestions. One can utilize the identified glycosylation marker, for example, for diagnosing and/or monitoring cancer in a subject. One can also use the glycosylation marker to identify glycoprotein biomarkers that carry the glycosylation marker. Such biomarkers can also be used for monitoring and/or diagnosing cancer. The biomarker may also be a subset of glycoforms of a glycoprotein that are separated in trains of spots on 2D gel.